Short Interest in GlucoTrack, Inc. (NASDAQ:GCTK) Increases By 223.2%

GlucoTrack, Inc. (NASDAQ:GCTK) was the recipient of a large growth in short interest during the month of April. As of April 30th, there was short interest totaling 2,166,796 shares, a growth of 223.2% from the April 15th total of 670,479 shares. Based on an average daily volume of 9,640,460 shares, the short-interest ratio is currently 0.2 days. Currently, 114.0% of the shares of the stock are sold short.

GlucoTrack Price Performance

GCTK traded down $0.02 during midday trading on Friday, hitting $0.65. The company had a trading volume of 383,596 shares, compared to its average volume of 3,310,814. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.61 and a current ratio of 1.61. The company has a market capitalization of $1.26 million, a PE ratio of -0.01 and a beta of 0.78. GlucoTrack has a twelve month low of $0.58 and a twelve month high of $15.90. The firm’s 50-day simple moving average is $0.93 and its 200-day simple moving average is $2.99.

Institutional Investors Weigh In On GlucoTrack

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE increased its position in GlucoTrack by 102,125.0% in the 2nd quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock valued at $25,000 after acquiring an additional 4,085 shares in the last quarter. Boothbay Fund Management LLC acquired a new stake in GlucoTrack in the 4th quarter valued at about $52,000. Finally, Ikarian Capital LLC acquired a new stake in GlucoTrack in the 4th quarter valued at about $177,000. Institutional investors and hedge funds own 10.92% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of GlucoTrack in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, GlucoTrack presently has an average rating of “Sell”.

About GlucoTrack

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.